Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioLase

This article was originally published in The Gray Sheet

Executive Summary

Acquisition of Laser Skin Toner for roughly 1.7 mil. shares of BioLase stock is valued at about $6 mil. LST's laser "no-incision facelift" and stretch-mark removal system, which is currently pending FDA clearance, is anticipated to round out BioLase's newly formed Aesthetic Division and complement its DermaLase hydrokinetic system and Lazer ToothBrush tooth-whitening system, BioLase states

You may also be interested in...



Philips Adds Capsule Technologies To Connected Care Business

Philips will pay $635m for the Massachusetts-based developer of a platform that connects medical devices and electronic medical records in hospitals.

Hand Sanitizer Problems Prompt US FDA Guidance On Keeping Methanol Out Of Other OTC Drugs

Final guidance, for pharmaceutical alcohol used as an active or inactive ingredient in other drugs as well as hand sanitizers, “will help pharmaceutical manufacturers avoid using pharmaceutical alcohol contaminated with or substituted with methanol in drug products.”

Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula

Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology might eventually be recommended.

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel